Cinq ans de létrozole comparé au tamoxifène en tant que traitement adjuvant initial chez les femmes ménopausées atteintes d'un cancer du sein précoce endocrino-réceptif : mise à jour de l'étude BIG 1-98

Coates et al. (mercredi) ont étudié cette question.

www.synapsesocial.com/papers/69dd460d656f15f1fc100f97 — DOI: https://doi.org/10.1200/jco.2006.08.8617

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial· 2005 · 876 citations
2. Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?· 2006 · 62 citations
3. Switching to Anastrozole Versus Continued Tamoxifen Treatment of Early Breast Cancer: Preliminary Results of the Italian Tamoxifen Anastrozole Trial· 2005 · 448 citations
4. Switching to exemestane after 2–3 years of adjuvant tamoxifen prolongs disease-free survival, but not overall survival, in postmenopausal women surviving primary breast cancer, compared with continuous tamoxifen☆, ☆, ☆☆☆Abstracted from: Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081–92.· 2004 · 170 citations
5. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancer· 2003 · 857 citations